Table 1 Number and percent of Mendelian randomization analyses per grading category by exposure category
From: Systematic review of Mendelian randomization studies on risk of cancer
Exposure category | Robust evidence | Probable evidence | Suggestive evidence | Insufficient evidence | Non-evaluable |
|---|---|---|---|---|---|
Amino acids and derivatives | 0 (0) | 5 (1.82) | 0 (0) | 27 (2.66) | 210 (6.56) |
Anthropometrics | 16 (18.39) | 37 (13.45) | 16 (17.98) | 177 (17.42) | 299 (9.34) |
Circulating leukocyte telomere length | 13 (14.94) | 20 (7.27) | 1 (1.12) | 25 (2.46) | 68 (2.13) |
Clinical measurements | 2 (2.3) | 14 (5.09) | 5 (5.62) | 25 (2.46) | 53 (1.66) |
Diabetes and related biomarkers | 2 (2.3) | 22 (8) | 20 (22.47) | 121 (11.91) | 188 (5.88) |
Dietary intake and micronutrient concentrations | 7 (8.05) | 31 (11.27) | 8 (8.99) | 235 (23.13) | 371 (11.59) |
Fatty acids and derivatives | 0 (0) | 14 (5.09) | 6 (6.74) | 27 (2.66) | 187 (5.84) |
Growth factors | 1 (1.15) | 1 (0.36) | 1 (1.12) | 1 (0.1) | 72 (2.25) |
Inflammatory biomarkers | 0 (0) | 6 (2.18) | 3 (3.37) | 22 (2.17) | 347 (10.84) |
Lifestyle, education and behavior | 9 (10.34) | 48 (17.45) | 9 (10.11) | 66 (6.5) | 108 (3.38) |
Lipid metabolism biomarkers | 10 (11.49) | 35 (12.73) | 7 (7.87) | 144 (14.17) | 344 (10.75) |
Methylations | 0 (0) | 0 (0) | 0 (0) | 6 (0.59) | 23 (0.72) |
Other diseases and traits | 12 (13.79) | 21 (7.64) | 11 (12.36) | 67 (6.59) | 96 (3) |
Other metabolites/biomarkers | 0 (0) | 4 (1.45) | 0 (0) | 21 (2.07) | 783 (24.47) |
Reproductive factors | 2 (2.3) | 5 (1.82) | 1 (1.12) | 24 (2.36) | 29 (0.91) |
Steroids | 13 (14.94) | 12 (4.36) | 1 (1.12) | 28 (2.76) | 22 (0.69) |
Total | 87 (100) | 275 (100) | 89 (100) | 1016 (100) | 3200 (100) |